Mabgeek

Focus: Mabgeek is a Shanghai-based biotechnology company founded in 2016 specializing in monoclonal antibodies for immunology and respiratory indications. The company is early-stage with a focused pipeline in atopic dermatitis and asthma.

Immunology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Mabgeek

AI assessmentNot Hiring

No open roles listed right now. Follow Mabgeek to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MG-K10 humanized monoclonal antibody injection

Pharmacokinetics

N/A

Clinical Trials (1)

NCT06277284Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

N/A

Help build intelligence for Mabgeek

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to a focused mAb pipeline with multiple Phase 3 programs in high-incidence indications (atopic dermatitis, asthma)
Opportunity to contribute to drug development in immunology/respiratory, two major therapeutic areas with significant unmet need
Early-stage biotech environment in growth phase with potential for equity upside and expanded career scope

Watch Out For

No current active job postings and undisclosed employee count suggest limited hiring or organizational opacity
Pre-revenue status with no disclosed funding raises questions about financial runway and operational stability
Minimal published scientific output (0 publications on record) and lack of recent news coverage indicate low visibility in the biotech ecosystem

Generated by Claude from Mabgeek's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MG-ZG122 Humanized Monoclonal Antibody Injection

Asthma

Phase 1

Clinical Trials (1)

NCT05659927Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects

Phase 1

MG-K10

Atopic Dermatitis

Phase 1/2

Clinical Trials (3)

NCT07540442A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Phase 3